Teva Reports New TEV-749 Olanzapine LAI Clinical Data

Tel Aviv, Israel, September18, 2026

Teva Advances Long-Acting Olanzapine Development

TEV-‘749 is being developed as a long-acting injectable formulation of olanzapine, an established atypical antipsychotic used in the treatment of schizophrenia and other psychiatric conditions. Long-acting injectable medicines can help address challenges associated with daily oral treatment by providing medication at longer intervals and supporting consistent exposure to therapy. The Phase 3 SOLARIS trial evaluated the efficacy and safety of TEV-‘749 in adults with schizophrenia who had been stabilized on oral olanzapine before entering the randomized portion of the study. The clinical program was designed to evaluate whether patients could maintain symptom control while receiving the investigational long-acting formulation.

Teva’s newly reported post hoc analyses examined stabilization and response outcomes among patients participating in the trial. According to the company, the analyses showed that a high proportion of patients receiving TEV-‘749 achieved or maintained clinically relevant levels of symptom stability during treatment. The data provide additional insight into treatment patterns within the Phase 3 population, although post hoc analyses are exploratory and should be interpreted in the context of the original study design.

TEV-‘749 Shows High Rates of Stabilization

One of the key findings highlighted by Teva was the high rate of symptom stabilization observed among patients receiving TEV-‘749. The company reported that more than 90% of patients remained stabilized following treatment, based on predefined clinical measures used in the study. Additional analyses examined the proportion of patients achieving clinically meaningful improvement in symptoms. Teva reported that patients receiving TEV-‘749 demonstrated high rates of response and sustained symptom control over the course of treatment.

The results are relevant to schizophrenia management because maintaining stable disease control can be an important component of long-term treatment. Treatment adherence and persistence can be challenging for some patients receiving daily oral antipsychotics, and LAI formulations are designed to provide an alternative approach to medication administration. However, the findings are derived from post hoc analyses rather than a prospectively defined primary endpoint. The results therefore provide additional context about the Phase 3 data but do not independently establish comparative effectiveness against other antipsychotic therapies.

Teva Expands Schizophrenia Treatment Pipeline

Teva is developing TEV-‘749 as part of its broader focus on central nervous system and psychiatric medicines. The investigational therapy uses olanzapine, a well-established antipsychotic, in a long-acting formulation designed to provide sustained drug exposure. The company has emphasized the potential clinical value of a long-acting olanzapine formulation that can provide patients and healthcare professionals with another treatment-delivery option. If approved, TEV-‘749 could potentially expand the range of LAI antipsychotic formulations available for adults with schizophrenia. The SOLARIS Phase 3 program represents an important part of the development pathway for TEV-‘749. Clinical studies are designed to evaluate the candidate’s safety, efficacy and ability to maintain symptom control in adults with schizophrenia. Additional analyses from the program may help characterize patient outcomes and treatment response across different clinical measures.

For patients living with schizophrenia, maintaining symptom stability can be important for supporting daily functioning and reducing the risk of disease worsening. Long-acting treatment approaches may also help simplify medication administration for some patients, although treatment decisions remain individualized and should consider clinical history, tolerability and patient preferences. Teva’s presentation of the new TEV-‘749 post hoc data at Psych Congress 2026 adds further information to the clinical development program for its investigational long-acting olanzapine formulation. The findings highlight high reported rates of stabilization and response in the studied population, while ongoing clinical and regulatory evaluation will determine the future development and potential approval of TEV-‘749. The program reflects continued pharmaceutical research into long-acting injectable antipsychotic therapies, with the goal of developing treatment options that can support sustained symptom control and address practical challenges associated with long-term schizophrenia management.

Source: Teva Pharmaceutical press release